CHARLES RIVER LABORATORIES INTERNATIONAL INC
For the period ended Dec 28, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
CRL$345.80-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for fiscal years
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows relating to operating activities | |||
| Net income | $25,291 | $480,370 | $492,608 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 361,741 | 314,124 | 303,870 |
| Goodwill impairment | 215,000 | — | — |
| Long-lived asset impairments | 51,825 | 41,911 | 5,816 |
| Stock-based compensation | 69,891 | 72,048 | 73,617 |
| Deferred income taxes | (67,428) | (50,903) | (35,884) |
| Write down of inventories | 46,992 | 6,290 | 5,973 |
| (Gain) loss on venture capital and strategic equity investments, net | 12,910 | (97,827) | 26,775 |
| Provision for credit losses | 14,774 | 18,225 | 6,706 |
| Loss (gain) on divestitures, net | 659 | 961 | (123,405) |
| Other, net | 33,251 | 1,079 | 16,118 |
| Changes in assets and liabilities: | |||
| Trade receivables and contract assets, net | 21,612 | (33,434) | (150,570) |
| Inventories | 16,804 | (62,301) | (78,523) |
| Accounts payable | (14,271) | (20,427) | (2,652) |
| Accrued compensation | (27,604) | 12,447 | (42,164) |
| Deferred revenue | 18,541 | (21,743) | 57,658 |
| Customer contract deposits | 6,584 | (15,564) | 30,457 |
| Other assets and liabilities, net | (51,995) | 38,642 | 33,240 |
| Net cash provided by operating activities | 734,577 | 683,898 | 619,640 |
| Cash flows relating to investing activities | |||
| Acquisition of businesses and assets, net of cash acquired | (5,479) | (194,785) | (283,392) |
| Capital expenditures | (232,967) | (318,528) | (324,733) |
| Purchases of investments and contributions to venture capital investments | (52,876) | (54,215) | (158,274) |
| Proceeds from sale of investments | 41,687 | 6,667 | 4,549 |
| Proceeds from sale of businesses, net | — | — | 163,275 |
| Other, net | 4,549 | (2,294) | (9,347) |
| Net cash used in investing activities | (245,086) | (563,155) | (607,922) |
| Cash flows relating to financing activities | |||
| Proceeds from long-term debt and revolving credit facility | 1,081,581 | 776,353 | 2,952,430 |
| Proceeds from exercises of stock options | 23,878 | 25,597 | 25,110 |
| Payments on long-term debt, revolving credit facility, and finance lease obligations | (1,493,769) | (851,676) | (2,932,636) |
| Purchase of treasury stock | (119,175) | (24,155) | (38,651) |
| Payments of contingent consideration | — | (2,711) | (10,356) |
| Purchase of remaining equity interest of other redeemable noncontrolling interest | (12,000) | (4,784) | (30,533) |
| Other, net | (31,442) | (4,145) | (7,761) |
| Net cash used in financing activities | (550,927) | (85,521) | (42,397) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (17,474) | 8,044 | 25,579 |
| Net change in cash, cash equivalents, and restricted cash | (78,910) | 43,266 | (5,100) |
| Cash, cash equivalents, and restricted cash, beginning of period | 284,480 | 241,214 | 246,314 |
| Cash, cash equivalents, and restricted cash, end of period | $205,570 | $284,480 | $241,214 |
| See Notes to Consolidated Financial Statements. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.